MetaCap

CalciMedica (CALC) vs Lexaria Bioscience (LEXX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CalciMedica is the larger company by market cap ($8.7 million vs $8.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CALC-14.86%LEXX+16.47%
+39%+2%-34%
Oct 7, 20261 yearNov 20, 2026
CALC-0.79%LEXX+21.39%
+38%+9%-21%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CALC versus LEXX key metrics
MetricCALCLEXX
Share price$1.26$4.03
Market cap$8.69M$8.49M
1-day change+7.69%-10.24%
YTD return-96.18%—
1-year return-92.34%—
EPS (TTM)$-4.41$-5.10
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$705.92K
Revenue growth (YoY)—+52.05%
Net income (latest FY)$-29.56M$-11.90M
Gross margin—99.61%
Operating margin—-1683.01%
Net margin—-1686.00%
52-week high$36.00$21.60
52-week low$1.00$2.43
Distance from 52-week high-96.50%-81.34%
Analyst consensusnonenone
Avg. price target upside+3868.25%+1947.15%
Average volume80.15K70.52K
Shares outstanding6.90M2.11M
Employees157
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About CalciMedica

CALC stock →

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

About Lexaria Bioscience

LEXX stock →

Lexaria Bioscience Corp. operates as a biotechnology company.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

CALC vs LEXX FAQ

Which is bigger, CalciMedica or Lexaria Bioscience?

CalciMedica (CALC) is larger, with a market capitalization of $8.69M compared with $8.49M for Lexaria Bioscience (LEXX).

Are CalciMedica and Lexaria Bioscience in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons